nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Advanced engineered nanoparticulate platforms to address key biological barriers for delivering chemotherapeutic agents to target sites
|
Cao, Jun |
|
|
167 |
C |
p. 170-188 |
artikel |
2 |
Antifibrotic strategies for medical devices
|
Welch, Nicholas G. |
|
|
167 |
C |
p. 109-120 |
artikel |
3 |
Clinically established biodegradable long acting injectables: An industry perspective
|
Nkanga, Christian Isalomboto |
|
|
167 |
C |
p. 19-46 |
artikel |
4 |
Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals
|
Sécher, T. |
|
|
167 |
C |
p. 148-169 |
artikel |
5 |
Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy
|
Nakamura, Takashi |
|
|
167 |
C |
p. 78-88 |
artikel |
6 |
Editorial board members
|
|
|
|
167 |
C |
p. ii |
artikel |
7 |
Engineering the drug carrier biointerface to overcome biological barriers to drug delivery
|
Finbloom, Joel A. |
|
|
167 |
C |
p. 89-108 |
artikel |
8 |
In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation
|
Newman, Stephen P. |
|
|
167 |
C |
p. 135-147 |
artikel |
9 |
Live long and active: Polypeptide-mediated assembly of antibody variable fragments
|
Lee, Changrim |
|
|
167 |
C |
p. 1-18 |
artikel |
10 |
Near-infrared fluorescence imaging in immunotherapy
|
Ji, Yuanyuan |
|
|
167 |
C |
p. 121-134 |
artikel |
11 |
Peptide and peptide-based inhibitors of SARS-CoV-2 entry
|
Schütz, Desiree |
|
|
167 |
C |
p. 47-65 |
artikel |
12 |
Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge
|
Sánchez-Félix, Manuel |
|
|
167 |
C |
p. 66-77 |
artikel |